Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov;26(11):1336-44.
doi: 10.1007/s11606-011-1757-y. Epub 2011 Jun 7.

Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis

Scot H Simpson  1 , John-Michael Gamble, Laurie Mereu, Thane Chambers
Affiliations
Review

Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis

Scot H Simpson et al. J Gen Intern Med. 2011 Nov.

Abstract

Objectives: Pharmacologic evidence suggests adequate antiplatelet activity in diabetic patients requires >100 mg aspirin daily, yet recent trials have used ≤100 mg daily. This meta-analysis explored the relationship between aspirin dose and prevention of cardiovascular events.

Data sources: Six electronic databases were searched using database-appropriate terms for aspirin, diabetes, and comparative study from inception until February 2010.

Review methods: Randomized controlled trials and cohort studies comparing aspirin to no antiplatelet therapy were included if they reported cardiovascular events as pre-specified outcomes, aspirin dose, and number of diabetic patients. Studies were stratified by daily aspirin dose (≤100 mg; 101-325 mg; >325 mg) and pooled risk ratios (RR) were calculated using random effects models. All-cause mortality was the primary outcome of interest. Cardiovascular-related mortality, myocardial infarction, and stroke were secondary outcomes.

Results: Data for diabetic patients were available from 21 studies (n = 17,522). Overall, 1,172 (15.4%) of 7,592 aspirin users and 1,520 (18.4%) of 8,269 controls died (p = 0.31). The pooled RRs were 0.89 (95% CI: 0.72-1.10; p = 0.27) from 13 studies using ≤100 mg (I(2) = 64%); 0.89 (95% CI: 0.61-1.30; p = 0.55) from four studies using 101-325 mg (I(2) = 83%); and 0.96 (95% CI: 0.85-1.08; p = 0.50) from eight studies using >325 mg (I(2) = 0%). Aspirin use was associated with a significantly lower risk of mortality (RR: 0.82; 95% CI: 0.69-0.98; p = 0.03) in 13 secondary prevention studies (I(2) = 27%), whereas aspirin use in seven primary prevention studies (I(2) = 0%) was not (RR: 1.01; 95% CI 0.85-1.19; p = 0.94). A substantial amount of heterogeneity was observed amongst studies in all outcomes. Although inclusion of cohort studies was a major source of heterogeneity, stratification by study design did not reveal a significant dose-response relationship.

Conclusions/interpretation: This summary of available data does not support an aspirin dose-response effect for prevention of cardiovascular events in diabetic patients. However, the systematic review identified an important gap in randomized controlled trial evidence for using 101-325 mg aspirin daily in diabetes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Citation flow diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Japanese Clinical Practice Guideline for Diabetes 2019.
    Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Araki E, et al. J Diabetes Investig. 2020 Jul;11(4):1020-1076. doi: 10.1111/jdi.13306. J Diabetes Investig. 2020. PMID: 33021749 Free PMC article. No abstract available.
  • Japanese Clinical Practice Guideline for Diabetes 2019.
    Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa Y, Tobe K, Yoshioka N. Araki E, et al. Diabetol Int. 2020 Jul 24;11(3):165-223. doi: 10.1007/s13340-020-00439-5. eCollection 2020 Jul. Diabetol Int. 2020. PMID: 32802702 Free PMC article. Review. No abstract available.
  • Effect of low-dose aspirin on health outcomes: An umbrella review of systematic reviews and meta-analyses.
    Veronese N, Demurtas J, Thompson T, Solmi M, Pesolillo G, Celotto S, Barnini T, Stubbs B, Maggi S, Pilotto A, Onder G, Theodoratou E, Vaona A, Firth J, Smith L, Koyanagi A, Ioannidis JPA, Tzoulaki I. Veronese N, et al. Br J Clin Pharmacol. 2020 Aug;86(8):1465-1475. doi: 10.1111/bcp.14310. Epub 2020 Jun 2. Br J Clin Pharmacol. 2020. PMID: 32488906 Free PMC article. Review.
  • Type 2 Diabetes: How Much of an Autoimmune Disease?
    de Candia P, Prattichizzo F, Garavelli S, De Rosa V, Galgani M, Di Rella F, Spagnuolo MI, Colamatteo A, Fusco C, Micillo T, Bruzzaniti S, Ceriello A, Puca AA, Matarese G. de Candia P, et al. Front Endocrinol (Lausanne). 2019 Jul 4;10:451. doi: 10.3389/fendo.2019.00451. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31333589 Free PMC article.
  • Japanese Clinical Practice Guideline for Diabetes 2016.
    Haneda M, Noda M, Origasa H, Noto H, Yabe D, Fujita Y, Goto A, Kondo T, Araki E. Haneda M, et al. Diabetol Int. 2018 Mar 27;9(1):1-45. doi: 10.1007/s13340-018-0345-3. eCollection 2018 Feb. Diabetol Int. 2018. PMID: 30603347 Free PMC article. Review. No abstract available.
See all "Cited by" articles

References

    1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee Vascular protection in people with diabetes. Can J Diabetes. 2008;32(suppl 1):S102–S106. - PubMed
    1. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–172. doi: 10.2337/dc07-9917. - DOI - PubMed
    1. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J. 2007;28(1):88–136. doi: 10.1093/eurheartj/ehm124. - DOI - PubMed
    1. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921):81–106. - PMC - PubMed
    1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71–86. - PMC - PubMed

MeSH terms